Want to see NVAX full AI Analyst Report?
Earnings Data
Report Date
Aug 12, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.4Last Year’s EPS
0.62Same Quarter Last Year
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized strong strategic progress: rapid expansion of partner collaborations, material partner-driven revenue growth, improved cash position and meaningful reductions in operating costs. Management showcased encouraging preclinical data (notably for a prioritized C. difficile asset) and reiterated 2026 guidance while outlining a credible path to non-GAAP profitability by 2028. Near-term challenges include a large YoY revenue decline driven by a prior-period noncash item, modest direct product sales, continued reliance on partners to convert MTAs to licensed programs and some near-term expense support for partners. On balance, the highlights—particularly partnership momentum, partner-revenue growth, cash runway and cost reductions—substantially outweigh the lowlights, though execution and timing risks remain.Company Guidance
Strategic Partnering Momentum
Signed multiple partnerships and MTAs: new nonexclusive Pfizer license (received $30M upfront, eligible for up to $250M in development/sales milestones per asset and royalties up to 20 years), deepened Sanofi collaboration, 4 new MTAs in early 2026 including a top-10 oncology pharma, and licensing/MTA coverage across 4 of the top 10 global pharma companies enabling exploration of >30 unique indications.
Partner-Related Revenue Growth
Partner-related revenue drivers grew strongly in Q1 2026: supply sales of $33M (up 139% YoY) and licensing/royalties/other revenue of $97M (up 116% YoY), reflecting successful commercialization of the Matrix-M model.
Cash Position and Non-dilutive Funding
Ended Q1 2026 with $818M in cash and accounts receivable and added $80M of nondilutive cash in the quarter (including $30M Pfizer upfront and a $50M initial draw on a $330M credit facility), supporting an estimated cash runway into 2028 without additional partner upfronts/milestones.
Cost Structure Improvements
Significant cost reductions: combined R&D and SG&A (non-GAAP, net of reimbursements) down 23% year-over-year; non-GAAP R&D down 13%; GAAP SG&A down 40% — part of a multi-year plan to lower operating expenses (2026/2027 guidance reiterated; 2028 non-GAAP R&D + SG&A guidance refined to $150M–$200M).
Reiterated 2026 Financial Guidance
Reiterated full-year 2026 adjusted total revenue framework of $230M–$270M (midpoint $250M). Recorded $119M through Q1, leaving ~$131M at midpoint to recognize over the remaining three quarters (~$44M/quarter).
Path Toward Profitability
Reported a relatively small Q1 2026 net loss of $9M and management reiterated the goal of achieving non-GAAP P&L profitability as early as 2028, driven by partner monetization and continued cost reductions.
R&D Prioritization and Data-Driven Innovation
Prioritized a multivalent C. difficile vaccine candidate for IND-enabling studies targeting clinic entry as early as 2027 based on encouraging preclinical data (strong antitoxin IgG responses, mucosal immunity assessments, improved survival vs comparator). Continued positive preclinical work on RSV and VZV and efforts to expand and tailor Matrix-M adjuvant utility.
Clinical and Real-World Differentiation Evidence
Partner Sanofi's Phase IV COMPARE study showed Nuvaxovid had statistically fewer side effects than Moderna's mNEXSPIKE; SHIELD real-world data (with University of Utah) reported fewer side effects and half as many hours of lost work for Nuvaxovid recipients vs mRNA — supporting Matrix-M's favorable reactogenicity profile and partner interest.
NVAX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NVAX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2026 | $8.10 | $9.36 | +15.56% |
Feb 26, 2026 | $9.53 | $11.19 | +17.42% |
Nov 06, 2025 | $7.69 | $7.59 | -1.30% |
Aug 06, 2025 | $6.73 | $7.58 | +12.63% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Novavax (NVAX) report earnings?
Novavax (NVAX) is schdueled to report earning on Aug 12, 2026, After Close (Confirmed).
What is Novavax (NVAX) earnings time?
Novavax (NVAX) earnings time is at Aug 12, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NVAX EPS forecast?
NVAX EPS forecast for the fiscal quarter 2026 (Q2) is -0.4.
